Mesoblast’s $90 Million Refinancing and Expansion of Senior Debt Facility

Latham & Watkins represented Mesoblast in the transaction.Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has successfully…

This content is for members only.
Login to Read More Join Now
Laura Testa

Author: Laura Testa

This content is for members only.
Login to Read More Join Now